

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

^{Pr}**CISPLATIN INJECTION**

Cisplatin Injection

Solution, 1 mg / mL (10 mg, 50 mg and 100 mg cisplatin per vial), Intravenous

Teva Standard

Antineoplastic Agent

Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
Canada M1B 2K9

Date of Initial Authorization:
March 15, 2013

Date of Revision:
JUN 25, 2024

Submission Control Number: 280856

RECENT MAJOR LABEL CHANGES

3 SERIOUS WARNINGS AND PRECAUTIONS BOX	06/2024
7 WARNINGS AND PRECAUTIONS	06/2024

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics	4
1.2 Geriatrics	4
2 CONTRAINDICATIONS	4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX	5
4 DOSAGE AND ADMINISTRATION	5
4.2 Recommended Dose and Dosage Adjustment.....	5
4.3 Reconstitution	6
4.4 Administration.....	6
5 OVERDOSAGE	6
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	7
7 WARNINGS AND PRECAUTIONS	7
7.1 Special Populations.....	15
7.1.1 Pregnant Women	15
7.1.2 Breast-feeding	15
7.1.3 Pediatrics	15
7.1.4 Geriatrics	15
8 ADVERSE REACTIONS	15
9 DRUG INTERACTIONS	19

9.2 Drug Interactions Overview	19
9.4 Drug-Drug Interactions	19
9.5 Drug-Food Interactions.....	20
9.6 Drug-Herb Interactions.....	20
9.7 Drug-Laboratory Test Interactions.....	20
10 CLINICAL PHARMACOLOGY	20
10.1 Mechanism of Action.....	20
10.2 Pharmacodynamics.....	20
10.3 Pharmacokinetics	21
11 STORAGE, STABILITY AND DISPOSAL	22
12 SPECIAL HANDLING INSTRUCTIONS	22
PART II: SCIENTIFIC INFORMATION	23
13 PHARMACEUTICAL INFORMATION	23
14 CLINICAL TRIALS	24
15 MICROBIOLOGY	24
16 NON-CLINICAL TOXICOLOGY	24
17 SUPPORTING PRODUCT MONOGRAPHS	25
PATIENT MEDICATION INFORMATION	26

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

CISPLATIN INJECTION is indicated as palliative therapy, to be employed in addition to other modalities, or in established combination therapy with other chemotherapeutic agents in the following:

- **Metastatic Testicular Tumors:** In patients who have already received appropriate surgical and/or radiotherapeutic and/or chemotherapeutic procedures.
- **Metastatic Ovarian Tumors:** As secondary therapy in patients refractory to standard chemotherapy.
- **Advanced Bladder Cancer:** As a single agent for patients with transitional cell bladder cancer.

1.1 Pediatrics

Ototoxic effects may be more severe in children particularly in patients less than 5 years of age (see [7.1.3 Special Populations – Pediatrics](#)).

1.2 Geriatrics

Geriatric patients, patients with baseline renal impairment, patients who are taking other nephrotoxic drugs, or patients who are not well hydrated may be more susceptible to nephrotoxicity. Geriatric patients may be more susceptible to myelosuppression. Geriatric patients may be more susceptible to peripheral neuropathy. See [7.1.4 Special Populations – Geriatric](#).

2 CONTRAINDICATIONS

- CISPLATIN INJECTION is contraindicated in patients with pre-existing renal impairment and hearing impairment, unless in the judgement of the physician and patient, the possible benefits of treatment outweigh the risks.
- CISPLATIN INJECTION should not be employed in myelosuppressed patients
- CISPLATIN INJECTION is contraindicated in individuals who have demonstrated a previous hypersensitivity to it or other platinum-containing compounds or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container (see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#)).

When used as indicated, the physician must carefully weigh the therapeutic benefit versus risk of toxicity which may occur.

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

CISPLATIN INJECTION IS A CYTOTOXIC DRUG THAT MUST BE ADMINISTERED ONLY BY PHYSICIANS EXPERIENCED WITH CANCER CHEMOTHERAPEUTIC DRUGS. BLOOD COUNTS AS WELL AS RENAL AND HEPATIC FUNCTION TESTS SHOULD BE TAKEN REGULARLY. DISCONTINUE THE DRUG IF ABNORMAL DEPRESSION OF BONE MARROW OR ABNORMAL RENAL OR HEPATIC FUNCTION IS SEEN.

- Anaphylactic-like reactions (see [7 WARNINGS AND PRECAUTIONS](#) and [8 ADVERSE REACTIONS](#))
- Infections, such as sepsis, including fatal cases (see [7 WARNINGS AND PRECAUTIONS](#) and [8 ADVERSE REACTIONS](#))
- Myelosuppression (including fatal cases) such as neutropenia, leukopenia, thrombocytopenia (see [7 WARNINGS AND PRECAUTIONS](#) and [8 ADVERSE REACTIONS](#))
- Neurotoxicity (see [7 WARNINGS AND PRECAUTIONS](#) and [8 ADVERSE REACTIONS](#)):
 - Leukoencephalopathy, including fatal case
 - Peripheral neuropathy
 - Posterior reversible encephalopathy syndrome, including fatal cases
- Renal toxicity (see [2 CONTRAINDICATIONS](#), [7 WARNINGS AND PRECAUTIONS](#) and [8 ADVERSE REACTIONS](#))
- Cardiovascular toxicity, such as venous thromboembolic events and pulmonary embolism, including fatal cases (see [7 WARNINGS AND PRECAUTIONS](#) and [8 ADVERSE REACTIONS](#))
- Administration of cisplatin prior to an infusion with paclitaxel may increase exposure to paclitaxel by 33% and can therefore intensify neutropenia and neurotoxicity.

4 DOSAGE AND ADMINISTRATION

4.2 Recommended Dose and Dosage Adjustment

The recommended dose of CISPLATIN INJECTION in adults and children as single-agent therapy is 50 to 75 mg/m² as a single intravenous dose every 3 to 4 weeks, or 15 to 20 mg/m² intravenous daily for 5 days, every 3 to 4 weeks.

A repeat course of CISPLATIN INJECTION should not be given until the serum creatinine is below 1.5 mg/100 mL and/or the BUN is below 25 mg/100 mL. A repeat course should not be given until circulating blood elements are at an acceptable level (platelets \geq 100,000 cells/mm³, WBC \geq 4,000 cells/mm³). Subsequent dose of CISPLATIN INJECTION should not be given until an audiometric analysis indicates that auditory acuity is within normal limits.

When employed in combination with other antitumor drugs, the dose of CISPLATIN INJECTION should be adjusted appropriately.

4.3 Reconstitution

Preparation of intravenous solutions

IV needles, syringes or sets having aluminum components should not be employed in preparation or administration of CISPLATIN INJECTION solutions. An interaction will occur between aluminum and platinum from cisplatin, causing formation of a black precipitate, which is visible in the reconstituted solution, and a loss of potency.

Dilute the prepared CISPLATIN INJECTION in 2 liters of 5% dextrose in one half or one third normal saline, containing 37.5 g of mannitol.

Diluted CISPLATIN INJECTION solution is suitable for intravenous infusion. This solution is not preserved and it should be used within 24 hours. Any unused portion should be discarded after that time, in order to avoid risk of microbial contamination.

As with all parenteral drug products, intravenous admixtures should be inspected visually for clarity, particulate matter, precipitate, discoloration and leakage prior to administration, whenever solution and container permit. Solutions showing haziness, particulate matter, precipitate, discoloration or leakage should not be used.

4.4 Administration

Pre-treatment hydration with 1 to 2 L of fluid infused for 8 to 12 hours prior to a cisplatin dose is recommended. The drug is then diluted in 2 liters of 5% dextrose in 1/2 or 1/3 normal saline containing 37.5 g of mannitol, and infused over a 6 to 8-hour period. Adequate hydration and urinary output must be maintained during the following 24 hours.

Cisplatin is a cytotoxic agent. Caution should be utilized during handling and preparation. Use of gloves and other protective clothing to prevent skin contact is recommended (see [4.3 Reconstitution](#) and [7 WARNINGS AND PRECAUTIONS, General](#) and [12 SPECIAL HANDLING INSTRUCTIONS](#)). If cisplatin solution contacts the skin, immediately wash thoroughly with soap and water. If cisplatin solution contacts mucous membranes, flush thoroughly with water.

5 OVERDOSAGE

CAUTION SHOULD BE USED TO PREVENT INADVERTENT OVERDOSAGE WITH CISPLATIN INJECTION.

Acute overdosage with this drug may result in kidney failure, liver failure, deafness, ocular toxicity (including detachment of the retina), significant myelosuppression, intractable nausea and vomiting and/or neuritis. In addition, death can occur following overdosage.

No proven antidote has been established for cisplatin overdosage. Hemodialysis, even when initiated for hours after overdosage, appears to have little effect on removing platinum from the body because of rapid and high degree of protein binding of cisplatin. Management of overdosage should include general supportive measures to sustain the patient through the period of toxicity that may occur. Patients should be monitored for 3-4 weeks in case of delayed toxicity.

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength / Composition	Non-medicinal Ingredients
Intravenous infusion	Sterile solution 1 mg/mL cisplatin	Hydrochloric Acid or Sodium Hydroxide is added as a pH adjuster, 9 mg/mL of Sodium Chloride in Water for Injection.

CISPLATIN INJECTION (1 mg/mL) is supplied as a sterile aqueous solution for intravenous use, available in single use glass vials of 10 mL, 50 mL and 100 mL. Each single-use vial is individually packaged in a carton. CISPLATIN INJECTION is preservative-free. The cap colour of the 10 mL, 50 mL and 100 mL vials are yellow, blue and green, respectively.

7 WARNINGS AND PRECAUTIONS

See **3** [WARNINGS AND PRECAUTIONS BOX](#)

General

CISPLATIN INJECTION IS A CYTOTOXIC DRUG AND SHOULD BE USED ONLY BY PHYSICIANS EXPERIENCED WITH CANCER CHEMOTHERAPEUTIC DRUGS. BLOOD COUNTS AS WELL AS RENAL AND HEPATIC FUNCTION TESTS SHOULD BE TAKEN REGULARLY. DISCONTINUE THE DRUG IF ABNORMAL DEPRESSION OF BONE MARROW OR ABNORMAL RENAL OR HEPATIC FUNCTION IS SEEN.

CISPLATIN INJECTION should be administered under the supervision of a qualified physician experienced with the use of antineoplastic therapy. The benefit to patient versus risk of toxicity

must be carefully weighed. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.

An interaction will occur between aluminum and platinum from cisplatin, causing a black precipitate which is visible in the solution (see [4.3 Reconstitution, Preparation of intravenous solutions](#)).

As with other potentially toxic compounds, caution should be exercised in handling the solution of cisplatin (see [4.3 Reconstitution](#), [4.4 ADMINISTRATION](#), [7 WARNINGS AND PRECAUTIONS, General](#), [12 SPECIAL HANDLING INSTRUCTIONS](#)). Skin reactions associated with accidental exposure to cisplatin may occur. The use of gloves is recommended. If cisplatin solution contacts the skin, immediately wash thoroughly with soap and water. If cisplatin solution contacts mucous membranes, flush thoroughly with water.

Carcinogenesis and Mutagenesis

Cisplatin has been found to have carcinogenic potential in laboratory animals. There have been reports of acute myelogenous leukemias and myelodysplastic syndromes arising in patients who have been treated with cisplatin, mostly when given in combination with other potentially leukemogenic agents. The development of acute leukemia coincident with the use of cisplatin (secondary acute leukemia) has been reported in humans. In these reports cisplatin was generally given in combination with other leukemogenic agents (see [8 ADVERSE REACTIONS](#); [16 NON-CLINICAL TOXICOLOGY](#)).

Cardiovascular

Cisplatin has been found to be associated with cardiovascular toxicity (see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#) and [8 ADVERSE REACTIONS](#)). A significant increase in the risk of venous thromboembolic events has been reported in patients with advanced solid tumors and treated with cisplatin. Vascular toxicities have been reported. The events were clinically heterogeneous and included myocardial infarction, cerebrovascular accident (hemorrhagic and ischemic stroke), thrombotic microangiopathy (hemolytic uremic syndrome) or cerebral arteritis.

There are also reports of Raynaud's phenomenon occurring in patients treated with the combination of bleomycin, vinblastine with or without cisplatin. It has been suggested that hypomagnesemia can occur with the use of cisplatin. However, it is currently unknown if the cause of Raynaud's phenomenon in these cases is the disease, underlying vascular compromise, bleomycin, vinblastine, hypomagnesemia or a combination of any of these factors.

Cases of pulmonary embolism (including fatalities) have been reported (see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#) and [8 ADVERSE REACTIONS](#)).

Ear/Nose/Throat

Cisplatin for injection can cause ototoxicity, which is cumulative and may be severe. Ototoxicity has been observed in up to 31% of patients treated with a single dose of cisplatin, 50 mg/m², and is manifested by tinnitus and/or hearing loss in the high frequency range (4,000 to 8,000 Hz). Decreased ability to hear normal conversational tones may occur occasionally. Hearing loss can be unilateral or bilateral and tends to become more frequent and severe with repeated doses; however, deafness after the initial dose of cisplatin has been reported rarely. It is unclear whether cisplatin-induced ototoxicity is reversible. Additional risk factors for ototoxicity include simultaneous cranial irradiation, treatment with other ototoxic drugs and renal impairment.

Ototoxic effects may be more severe in children particularly in patients less than 5 years of age. The prevalence of hearing loss in pediatric patients is estimated to be 40-60%. Careful monitoring of audiometry should be performed prior to initiation of therapy and prior to subsequent doses of cisplatin. Vestibular toxicity has also been reported. Consider audiometric and vestibular testing in all pediatric patients receiving cisplatin.

Concurrent and/or sequential administration of ototoxic drugs such as aminoglycoside antibiotics or loop diuretics may increase the potential of cisplatin to cause ototoxicity, especially in the presence of renal impairment (see [9.4 Drug-Drug Interactions](#)). Ifosfamide may increase hearing loss due to cisplatin.

Gastrointestinal

Cisplatin is a highly emetogenic antineoplastic agent. Premedicate with anti-emetic agents. Marked nausea and vomiting occurred in almost all patients treated with cisplatin occasionally severe causing discontinuation. Nausea and vomiting may begin within 1 to 4 hours after treatment and last up to 72 hours. Maximal intensity occurs 48 to 72 hours after administration. Various degrees of vomiting, nausea, and/or anorexia may persist for up to 1 week after treatment. Delayed nausea and vomiting (beginning or persisting 24 hours or more after chemotherapy) have occurred in patients attaining complete emetic control on the day of cisplatin therapy. Consider the use of additional anti-emetics following infusion. Diarrhea and stomatitis have also been reported. See [8 ADVERSE REACTIONS](#).

Hematologic

Myelosuppression occurs in 25 to 30% of patients treated with cisplatin. WBC and platelet nadirs generally occur after about 2 weeks with levels returning to pre-treatment values in most patients within 4 weeks. Cisplatin may cause anemia, which is occasionally caused by hemolysis. The nadirs in circulating platelets and leukocytes occur between days 18 and 23 (range 7.5 to 45), with most patients recovering by day 39 (range 13 to 62) (see [8 ADVERSE REACTIONS](#)).

Leukopenia and thrombocytopenia are dose-related, and may become clinically relevant in patients receiving high doses of cisplatin or in patients who have received prior

myelosuppressive treatments. Leukopenia and thrombocytopenia are more pronounced at higher doses (>50 mg/m²) (see [8 ADVERSE REACTIONS](#)).

Anemia (decrease of 2 g hemoglobin/100 mL) occurs at approximately the same frequency and with the same timing as leukopenia and thrombocytopenia.

Neutropenia, including fatal cases, has also been reported.

Cisplatin has been shown to sensitize red blood cells, sometimes resulting in a direct Coombs' positive hemolytic anemia. The incidence, severity and relative importance of this effect in relation to other hematologic toxicity has not been established, but the possibility of a hemolytic process should be considered in any person who is receiving cisplatin and has an unexplained fall in hemoglobin. The hemolytic process reverses on cessation of therapy.

Fever and infection have been reported in patients with neutropenia. Potential fatalities due to infection (secondary to myelosuppression) have been reported. Geriatric patients may be more susceptible to myelosuppression.

Perform standard hematologic tests before initiating cisplatin for injection, before each subsequent course, and as clinically indicated. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with cisplatin for injection. For patients who develop severe myelosuppression during treatment with cisplatin for injection, consider dose modifications and manage according to clinical treatment guidelines.

Hepatic

Transient elevation of hepatic enzymes and bilirubin can occur when cisplatin is administered in recommended doses.

Immune

Cisplatin for injection can cause severe hypersensitivity reactions, including anaphylaxis and death. Manifestations have included facial edema, wheezing, tachycardia, and hypotension. Hypersensitivity reactions have occurred within minutes of administration to patients with prior exposure to cisplatin for injection and have been alleviated by administration of epinephrine, corticosteroids and antihistamines.

Monitor patients receiving cisplatin for injection for possible hypersensitivity reactions. Ensure supportive equipment and medications are available to treat severe hypersensitivity reactions. Severe hypersensitivity reactions require immediate discontinuation of cisplatin for injection and aggressive therapy. Patients with a history of severe hypersensitivity reactions should not be rechallenged with cisplatin for injection (see [2 CONTRAINDICATIONS](#)). Cross-reactivity between platinum-based antineoplastic agents has been reported. Cases of severe

hypersensitivity reactions have recurred after rechallenging patients with a different platinum agent.

Infections and infestations

Infection and sepsis (including fatalities) have been reported. Tuberculosis has been reported.

Injection Site Reactions

Injection site reactions can occur during the administration of cisplatin for injection. Local soft tissue toxicity has been reported following extravasation of cisplatin for injection. Severity of the local tissue toxicity appears to be related to the concentration of the cisplatin for injection solution. Infusion of solutions with a cisplatin for injection concentration greater than 0.5 mg/mL may result in tissue cellulitis, fibrosis, necrosis, pain, edema, and erythema. Because of the possibility of extravasation, closely monitor the infusion site during drug administration.

Monitoring and Laboratory Tests

- Cisplatin produces cumulative nephrotoxicity which can be potentiated by aminoglycoside antibiotics. Serum creatinine, BUN, creatinine clearance, magnesium, sodium, potassium and calcium levels should be measured prior to initiating therapy and prior to each subsequent course.
- Ototoxicity of cisplatin is cumulative, audiometric testing should be performed prior to initiating therapy and prior to each subsequent dose of drug (see [8 ADVERSE REACTIONS](#)).
- Peripheral blood counts should be monitored weekly. Therapy should be interrupted accordingly.
- Liver function should be monitored periodically.
- Neurologic examinations should also be performed regularly (see [8 ADVERSE REACTIONS](#)).

Serum Electrolyte Disturbances:

Hypomagnesemia, hypocalcemia, hyponatremia, hypokalemia and hypophosphatemia have been reported to occur in patients treated with cisplatin and are probably related to renal tubular damage. Tetany has occasionally been reported in those patients with hypocalcemia and hypomagnesemia. Generally, normal serum electrolyte levels are restored by administering supplemental electrolytes and discontinuing cisplatin. Inappropriate antidiuretic hormone syndrome has also been reported.

Musculoskeletal and connective tissue disorders

Arthralgia/myalgia has been reported.

Neurologic

Cisplatin for injection can cause dose-related peripheral neuropathy that becomes more severe with repeated courses of the drug. Neuropathy can also have a delayed onset from 3 to 8 weeks after the last dose of cisplatin for injection. The neuropathy may progress further even after stopping treatment. These neuropathies may be irreversible and are seen as paresthesia in a stocking-glove distribution, areflexia, and loss of proprioception and vibratory sensation. Loss of motor function has also been reported. Serious events of leukoencephalopathy and posterior reversible encephalopathy syndrome including fatalities have been reported in post-market setting (see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#) AND [8 ADVERSE REACTIONS](#)).

Neurotoxicity, usually characterized by peripheral neuropathies, has occurred in some patients. Neuropathies resulting from cisplatin treatment may occur after prolonged therapy (4 to 7 months), however, neurologic symptoms have been reported to occur after a single dose. The neuropathy may progress after stopping the treatment. Lhermitte's sign, dorsal column myelopathy, autonomic neuropathy, leukoencephalopathy and posterior reversible encephalopathy syndrome have also been reported.

Cisplatin therapy should be discontinued when symptoms are first observed. Preliminary evidence suggests peripheral neuropathy may be irreversible in some patients.

Perform a neurological examination before initiating cisplatin for injection, at appropriate intervals during therapy, and after completion of therapy. Consider discontinuation of cisplatin for injection for patients who develop symptomatic peripheral neuropathy. Geriatric patients may be more susceptible to peripheral neuropathy.

Muscle cramps of sudden onset and short duration have been reported. These were usually observed in patients who had received a relatively high cumulative dose of cisplatin, and who had a relatively advanced stage of peripheral neuropathy.

Loss of taste, seizures, slurred speech and memory loss have also been reported.

Ocular Toxicity

Optic neuritis, papilledema and cerebral blindness have been reported infrequently in patients receiving standard recommended doses of cisplatin. Improvement and/or total recovery usually occurs after discontinuing cisplatin. Steroids, with or without mannitol, have been used, however, efficacy has not been established.

Blurred vision and altered color perception have been reported after the use of regimens with higher doses of cisplatin or greater dose frequencies than those recommended. The altered color perception manifests as a loss of color discrimination, particularly in the blue-yellow axis. The only finding on funduscopic exam is irregular retinal pigmentation of the macular area.

Other toxicities

Other toxicities reported to occur infrequently are cardiac abnormalities, hiccups, elevated serum amylase and rash. Alopecia has also been reported.

Local soft tissue toxicity has rarely been reported following extravasation of cisplatin. Infiltration of solutions of cisplatin may result in tissue cellulitis, fibrosis, necrosis, phlebitis, pain, edema and erythema. Pyrexia, asthenia, malaise have also been reported.

Renal

Ensure adequate hydration before, during, and after cisplatin for injection administration (see [4.4 ADMINISTRATION](#)). Cisplatin can cause severe renal toxicity, including acute renal failure.

At the recommended dosage, cisplatin should not be given more frequently than once every 3 to 4 weeks. Dose-related and cumulative renal insufficiency is the major dose-limiting toxicity of cisplatin. Renal toxicity has been noted in 28 - 36% of patients treated with a single dose of 50 mg/m². It is first noted during the second week after a dose and is manifested by elevations in BUN and creatinine, serum uric acid and/or a decrease in creatinine clearance. Renal toxicity becomes more prolonged and severe with repeated courses of the drug. Measure serum creatinine, blood urea nitrogen, creatinine clearance, and serum electrolytes including magnesium prior to initiating therapy, and as clinically indicated. Consider magnesium supplementation as clinically needed. Renal function must return to normal before another dose of cisplatin can be given.

Renal function impairment has been associated with renal tubular damage. The administration of cisplatin with a 6 - 8 hour infusion with intravenous hydration and mannitol diuresis has been used to reduce nephrotoxicity. However, renal toxicity still can occur after utilization of these procedures.

Patients with baseline renal impairment, geriatric patients, patients who are taking other nephrotoxic drugs, or patients who are not well hydrated may be more susceptible to nephrotoxicity.

Consider alternative treatments or reduce the dose of cisplatin for injection for patients with baseline renal impairment or who develop significant reductions in creatinine clearance during treatment with cisplatin for injection according to clinical treatment guidelines.

Aminoglycoside antibiotics, when given concurrently or within 1-2 weeks after cisplatin administration, may potentiate its nephrotoxic effects (see [9.4 Drug-Drug Interactions](#)). The renal toxicity of ifosfamide may be greater when used with cisplatin or in patients who have previously been given cisplatin.

Cisplatin may reduce the elimination of predominantly renal eliminated substances and enhance their toxicity. Reduction of the lithium blood levels was noticed in a few cases after treatment with cisplatin combined with bleomycin and etoposide. It is therefore recommended to monitor the lithium values.

Hyperuricemia has been reported to occur at approximately the same frequency as increases in BUN and serum creatinine. It is more pronounced after doses greater than 50 mg/m², and peak levels of uric acid generally occur between 3 to 5 days after the dose. Allopurinol therapy for hyperuricemia effectively reduces uric acid levels.

Reproductive Health: Female and Male Potential

Verify the pregnancy status of females of reproductive potential prior to initiation of cisplatin. Women of childbearing potential should use effective contraception during treatment with cisplatin and for at least 29 weeks (7 months) following the last dose. Abnormal spermatogenesis and azoospermia have been reported. Men with female partners of childbearing potential should be advised to use effective contraception during treatment with cisplatin and for at least 17 weeks (4 months) after the last dose.

Fertility

Cisplatin can cause abnormal spermatogenesis and azoospermia in male patients (see [7 WARNINGS AND PRECAUTIONS](#) and [8 ADVERSE REACTIONS](#)). Although the impairment of spermatogenesis can be reversible, males undergoing cisplatin treatment should be warned about the possible adverse effects on male fertility. Therefore, males receiving cisplatin must always be advised to use a condom during any sexual contacts with females of child-bearing potential. Patients should not donate semen while taking cisplatin and up to 2 years after. Patients should receive genetic counselling for increased risk for conception prior to cisplatin therapy and up to 2 years after initial treatment. If a pregnancy occurs in a partner of a male patient taking cisplatin, it is recommended to refer the female partner to a genetic counselling for evaluation and advice.

Based on non-clinical and clinical findings, female fertility may be compromised by treatment with cisplatin. Use of cisplatin has been associated with cumulative dose-dependent ovarian failure, premature menopause and reduced fertility.

Both men and women should seek advice on fertility preservation before treatment.

Respiratory, thoracic and mediastinal disorders

Pulmonary embolism (including fatalities) has been reported. Pulmonary toxicity has been reported in patients treated with cisplatin in combination with bleomycin or 5-fluorouracil.

7.1 Special Populations

7.1.1 Pregnant Women

Cisplatin can cause fetal harm when administered to a pregnant woman. Cisplatin is mutagenic in bacteria, produces chromosome aberrations in animal cells in tissue culture and is teratogenic and embryotoxic in mice. Patients should be advised to avoid becoming pregnant. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus (see [7 WARNINGS AND PRECAUTIONS, Carcinogenesis and Mutagenesis](#)).

7.1.2 Breast-feeding

Cisplatin and its active metabolites have been identified in human milk of treated mothers. Patients receiving cisplatin should not breastfeed during treatment and for 1 month following last dose of treatment. Treatment should be discontinued or stopped taking into account the importance of the drug to the patient.

7.1.3 Pediatrics

Ototoxicity, which is significant and may be more pronounced in children, is manifested by tinnitus and/or loss of high frequency hearing and occasionally deafness. Cases of delayed-onset hearing loss have been reported in the pediatric population. Long term follow-up in this population is recommended. Since ototoxicity is cumulative, audiometric testing should be performed prior to initiating therapy and prior to each subsequent dose of drug (see [7 WARNINGS AND PRECAUTIONS – Ear/Nose/Throat](#)).

7.1.4 Geriatrics

Geriatric patients, patients with baseline renal impairment, patients who are taking other nephrotoxic drugs, or patients who are not well hydrated may be more susceptible to nephrotoxicity (see [7 WARNINGS AND PRECAUTIONS – Renal](#)). Geriatric patients may be more susceptible to myelosuppression (see [7 WARNINGS AND PRECAUTIONS – Hematologic](#)). Geriatric patients may be more susceptible to peripheral neuropathy (see [7 WARNINGS AND PRECAUTIONS – Neurologic](#)).

8 ADVERSE REACTIONS

The most frequently reported undesirable effects after cisplatin (> 10%) were hematological (leukopenia, thrombocytopenia and anemia), gastrointestinal (anorexia, nausea, vomiting and diarrhoea), ear diseases (impaired hearing), kidney diseases (kidney failure, nephrotoxicity, hyperuricaemia and fever).

Toxic kidney, bone marrow and ear damage has been reported in up to one third of the patients after one single dose of cisplatin. The undesirable effects are generally dose-related and cumulative. Ototoxicity may be more severe in children.

The following serious adverse reactions have been reported (see [7 WARNINGS AND PRECAUTIONS](#)):

- Secondary acute leukemia (see [7 WARNINGS AND PRECAUTIONS – Carcinogenesis and Mutagenesis](#))
- Thromboembolic events (see [7 WARNINGS AND PRECAUTIONS – Cardiovascular](#))
- Ototoxicity (see [7 WARNINGS AND PRECAUTIONS – Ear/Nose/Throat](#))
- Nausea and vomiting (see [7 WARNINGS AND PRECAUTIONS – Gastrointestinal](#))
- Myelosuppression (see [7 WARNINGS AND PRECAUTIONS – Hematologic](#))
- Hypersensitivity reactions (see [7 WARNINGS AND PRECAUTIONS – Immune](#))
- Infections and sepsis: (see [7 WARNINGS AND PRECAUTIONS – Infections and infestations](#))
- Neurotoxicity (see [7 WARNINGS AND PRECAUTIONS – Neurologic](#))
- Ocular toxicities (see [7 WARNINGS AND PRECAUTIONS – Ocular toxicities](#))
- Extravasation (see [7 WARNINGS AND PRECAUTIONS – Other toxicities](#))
- Renal toxicity / nephrotoxicity (see [7 WARNINGS AND PRECAUTIONS – Renal](#))
- Pulmonary embolism (see [7 WARNINGS AND PRECAUTIONS – Respiratory](#))

The following undesirable effects were seen in the clinical studies with cisplatin injection and post-marketing. Frequency is defined as follows: very common ($\geq 1/10$), common ($\geq 1/100$ to $< 1/10$), uncommon ($\geq 1/1,000$ to $< 1/100$), rare ($\geq 1/10,000$ to $\leq 1/1,000$), very rare ($\leq 1/10,000$) and frequency not known (cannot be calculated from the available data).

Investigations	
Rare	Increased serum amylase, reduced albumin levels.
Very rare	Increased iron concentrations.
Cardiac disorders	
Common	Heart rhythm disturbances, including bradycardia and tachycardia, and other changes in the ECG e.g. ST segment changes, ischaemic symptoms*.
Rare	Myocardial infarction.
Very rare	Cardiac arrest.
Frequency not known	Heart disease.
Neoplasms benign, malignant and unspecified (incl. cysts and polyps)	
Rare	Acute leukaemia.
Blood and lymphatic system disorders	
Very common	Bone marrow failure, thrombocytopaenia, leukopenia and anaemia.
Rare	Coombs positive haemolytic anaemia, severe bone marrow suppression (including agranulocytosis, aplastic anaemia).

Rare - very rare	Thrombotic microangiopathy (haemolytic uraemic syndrome).
Frequency not known	Neutropenia.
Nervous system disorders	
Common	Neurotoxicity characterized by e.g. peripheral neuropathy (typically bilateral and sensory).
Uncommon	Neurotoxic symptoms (tremor, muscle weakness, autonomous neuropathy, myelopathy, Lhermitte's syndrome, optical neuritis, seizures).
Rare	Cerebrovascular event, loss of the sense of touch, loss of the sense of taste, cerebral arteritis, encephalopathy, occlusion of the carotid artery, cerebral dysfunction (confusion, slurred speech, memory loss, paralysis), leukoencephalopathy and reversible posterior leukoencephalopathy syndrome.
Very rare	Unilateral retrobulbar neuritis with loss of visual acuity.
Frequency not known	Cerebral haemorrhage, loss of the sense of taste caused by an ischaemic stroke.
Eye disorders	
Uncommon	Acquired colour blindness, papilledema.
Rare	Cortical blindness.
Rare - very rare	Varying degrees of loss of vision.
Frequency not known	Blurry vision, optical neuritis, pigmentation of the retina.
Ear and labyrinth disorders	
Very common	Ototoxicity, tinnitus, hearing loss.
Common	Deafness, vestibular toxicity.
Gastrointestinal disorders	
Very common	Vomiting, nausea, loss of appetite, diarrhoea.
Rare	Oral mucositis, stomatitis.
Frequency not known	Anorexia, hiccups.
Renal and urinary disorders	
Very common	Disrupted kidney function.
Common – very common	Tubular necrosis.
Frequency not known	Acute kidney failure, kidney failure (including an increase in blood urea and creatinine, serum uric acid and/or a drop in creatinine clearance), renal tubular disease.
Skin and subcutaneous tissue disorders	
Uncommon	Alopecia.
Frequency not known	Rash.
Musculoskeletal and connective tissue disorders	
Frequency not known	Muscle cramps, myalgia.
Endocrine disorders	
Uncommon	Hypersecretion of vasopressin (SIADH/Schwartz-Bartter syndrome).
Frequency not known	Elevated amylase in the blood

Metabolism and nutrition disorders	
Very common	Hyponatremia.
Common – very common	Hyperuricaemia.
Uncommon	Hypomagnesaemia, hypokalemia, hypophosphatemia, hypocalcaemia.
Rare	Tetany.
Frequency not known	Dehydration.
Infections and infestations	
Common	Sepsis.
Frequency not known	Infections (which may be fatal).
Vascular disorders	
Common	Venous thromboembolism.
Rare	Hypertension.
Rare – very rare	Raynaud's syndrome.
Very rare	Vascular disorders (cerebral or coronary ischemia, reduction of peripheral circulation related to Raynaud's syndrome).
Frequency not known	Thrombotic microangiopathy (hemolytic uraemic syndrome).
General disorders and administration site conditions	
Very common	Fever.
Common	Local oedemas, pain and erythema, necrosis and ulceration of the skin and phlebitis at the injection site.
Rare – very rare	Extravasation at the administration site with soft tissue injuries such as cellulitis and fibrosis.
Frequency not known	Fatigue, malaise.
Immune system disorders	
Uncommon	Allergic reactions may occur such as a rash, urticaria, erythema or pruritus. Anaphylactoid reactions (hypotension, tachycardia, dyspnoea, bronchospasm, wheezing breathing, facial oedema and fever have been reported).
Frequency not known	Flushing.
Hepatobiliary disorders	
Common	Reversible reduced liver function with an increase in liver enzymes and in the amount of bilirubin in the blood.
Respiratory, thoracic and mediastinal disorders	
Frequency not known	Lung embolism, pulmonary toxicity (in combination with bleomycin or 5-fluorouracil).
Reproductive system and breast disorders	
Uncommon	Disruption of spermatogenesis, ovulation disturbances, painful gynecomastia.
Frequency not known	Azoospermia.

*Has been reported especially when combined with other cytostatic drugs.

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

Cisplatin is usually combined with other cytostatic drugs with similar mechanisms of action. Additive toxicity may occur in such situations.

Concomitant use of bone marrow-suppressing drugs or radiation will enhance cisplatin's bone marrow suppressive effect.

9.4 Drug-Drug Interactions

- *Anticonvulsant agents.* Plasma levels of anticonvulsants may become subtherapeutic during cisplatin therapy. In a randomized trial in advanced ovarian cancer, response duration was adversely affected when pyridoxine was used with altretamine (hexamethylmelamine) and cisplatin. In patients receiving cisplatin and phenytoin, serum concentrations of the latter may be decreased, possibly as a result of decreased absorption and/or increased metabolism. Absorption of carbamazepine and valproate sodium has also been reported to be impaired. Adequate plasma level monitoring of anticonvulsants is essential during cisplatin therapy.
- *Nephrotoxic drugs.* Aminoglycoside antibiotics, when given concurrently or within 1-2 weeks after cisplatin administration, may potentiate its nephrotoxic effects (see [7 WARNINGS AND PRECAUTIONS](#)). The renal toxicity of ifosfamide may be greater when used with cisplatin or in patients who have previously been given cisplatin.
- *Renally excreted drugs.* Literature data suggest that cisplatin may reduce the elimination of predominantly renal eliminated substances and enhance their toxicity. Reduction of the lithium blood levels was noticed in a few cases after treatment with cisplatin combined with bleomycin and etoposide. It is therefore recommended to monitor the lithium values.
- *Ototoxic drugs.* Concurrent and/or sequential administration of ototoxic drugs such as aminoglycoside antibiotics or loop diuretics may increase the potential of cisplatin to cause ototoxicity, especially in the presence of renal impairment (see [7 WARNINGS AND PRECAUTIONS](#)). Ifosfamide may increase hearing loss due to cisplatin.
- *Anticoagulants.* It is necessary to check the INR when oral anticoagulants such as coumarins/warfarin are used simultaneously with cisplatin.
- *Paclitaxel.* Administration of cisplatin prior to an infusion with paclitaxel may increase exposure to paclitaxel by 33% and can therefore intensify neutropenia and neurotoxicity (see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#)).

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Cisplatin has biochemical properties similar to those of bifunctional alkylating agents producing inter-strand and intra-strand cross-links in DNA. It is apparently not cell-cycle specific. The main mechanism of the cytotoxic action involves the binding of cisplatin to genomic DNA in the cell nucleus to form interstrand and intrastrand cross-links. This interferes with normal transcription and/or DNA replication mechanisms and triggers cytotoxic processes that lead to cell death. Antitumor activity of cisplatin was first demonstrated against sarcoma 180 and L1210 leukemia.

10.2 Pharmacodynamics

Cisplatin causes immunosuppression, which is short-lived (18 - 72 hours) and followed by a rapid increase in host immune response. This increase in the host immune response has been postulated to cause tumor regression in animals.

Subsequent investigations have shown significant activity of cisplatin IP as single agent in several experimental tumors, as follows:

- (1) Transplantable animal tumors, including Walker 256 carcinosarcoma, Dunning ascitic leukemia, Lewis lung carcinoma, Ehrlich ascites tumor, P-388 leukemia, B-16 melanoma, and the intracerebrally implanted ependymoblastoma tumor in mice.
- (2) Chemically-induced primary tumors, including the 7, 12-dimethylbenzanthracene (DMBA)-induced mammary tumors in rats and the N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT)-induced murine bladder cancer.
- (3) The virally-induced Rous sarcoma.

Cisplatin has demonstrated synergism in activity against L1210 leukemia when combined with other chemotherapeutic agents including cyclophosphamide, ICRF-159, ifosfamide, cytosine

arabinoside, hydroxyurea, phosphoramide mustard, azacytidine, 5-fluorouracil, emetine, adriamycin and methotrexate. No apparent synergism was noted with BCNU.

10.3 Pharmacokinetics

Administration and Distribution:

Following bolus injection, or intravenous infusion over 2 to 7 hours, of doses ranging from 50 to 100 mg/m², plasma cisplatin half-life is approximately 30 minutes. The ratios of cisplatin to total, free (ultrafilterable) platinum in the plasma range from 0.4 to 1.1 after a dose of 100 mg/m². After a single IV injection of cisplatin in dogs, the rapid-phase half-time was less than one hour and the slow-phase half-time was approximately 5 days. Approximately 60-70% of the dose was recovered in the urine in the first four hours after treatment (2).

Cisplatin does not undergo instantaneous and reversible binding to plasma proteins characteristic of normal drug-protein binding. However, the platinum from cisplatin becomes bound to plasma proteins. These complexes are slowly eliminated with a half-life of 5 days or more.

Cisplatin was distributed in highest concentrations in kidney, liver, gonads, spleen and adrenals at early times (1-2 hours) after IV injection into dogs, but remained significantly elevated only in kidney, liver, ovary and uterus for up to six days post-treatment. The tissue:plasma ratio of platinum was 3:1 and 4:1 for liver and kidney, respectively, at 6 days post-treatment (2).

Following cisplatin doses of 20 to 120 mg/m², the concentrations of platinum are highest in liver, prostate and kidney, somewhat lower in bladder, muscle, testicle, pancreas and spleen and lowest in bowel, adrenal, heart, lung, cerebrum and cerebellum. Platinum is present in tissues for as long as 180 days after the last administration. With the exception of intracerebral tumors, platinum concentrations in tumors are generally somewhat lower than the concentrations in the organ where the tumor is located. Different metastatic sites in the same patient may have different platinum concentrations. Hepatic metastases have the highest platinum concentrations, but these are similar to the platinum concentrations in the normal liver.

Elimination:

Over a range of doses administered as bolus injections or infusions of up to 24 hours, approximately 10 to 40% of the platinum administered is excreted in the urine in 24 hours. Similar mean urinary recoveries of platinum are found following daily administration of five consecutive days. Intact cisplatin accounts for the majority of platinum excreted in the urine within one hour of administration. Renal clearance of cisplatin exceeds creatinine clearance. The renal clearance of free (ultrafilterable) platinum also exceeds creatinine clearance. Renal clearance is non-linear and depends on dose, urine flow rate and individual variability in tubular secretion and reabsorption. No close correlation exists between the renal clearance of either

free (ultrafilterable) platinum or cisplatin and creatinine clearance. There is a potential for accumulation of free (ultrafilterable) platinum in plasma when cisplatin is administered on a daily basis, but not when it is administered on an intermittent basis.

Although small amounts of platinum are present in the bile and large intestine after administration of cisplatin, fecal excretion of platinum appears to be insignificant.

11 STORAGE, STABILITY AND DISPOSAL

Unopened vials of CISPLATIN INJECTION are stored at room temperature between 15°C and 25°C. Storage of vials should not exceed 25°C. Do not refrigerate or freeze cisplatin solutions since a precipitate will form. Protect from light.

12 SPECIAL HANDLING INSTRUCTIONS

1. Preparation of CISPLATIN INJECTION should be done in a vertical laminar flow hood (Biological Safety Cabinet - Class II).
2. Cisplatin is cytotoxic. Personnel preparing CISPLATIN INJECTION should wear PVC gloves, safety glasses, disposable gowns, and masks.
3. All needles, syringes, vials and other materials which have come in contact with CISPLATIN INJECTION should be segregated and incinerated at 1000°C or more. Sealed containers may explode if tightly sealed. Intact vials should be returned to the manufacturer for destruction. Proper precautions should be taken in packaging these materials for transport.
4. Personnel regularly involved in the preparation and handling of CISPLATIN INJECTION should have bi-annual blood examinations.

PART II: SCIENTIFIC INFORMATION

13 PHARMACEUTICAL INFORMATION


Drug substance

Proper Name: Cisplatin

Chemical Name: 1) platinum, diamminedichloro-, cis
2) cis-diamminedichloroplatinum

Molecular formula and molecular mass: Pt N₂H₆Cl₂, 300.06 g/mol

Structural formula:



Physicochemical properties: Cisplatin is a heavy metal complex containing a central atom of platinum, surrounded by two chlorine atoms and two ammonia molecules in the cis position. It occurs as a yellow to orange crystalline powder and is slightly soluble in water, sparingly soluble in dimethyl-formamide and practically insoluble in ethanol.

14 CLINICAL TRIALS

This information is not available for this drug product.

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

General Toxicology:

Toxicological Parameters of Cisplatin

Intravenous Route

	Mice		Dogs				Monkeys	
	Single Dose		Single Dose		OD x 5 days		OD x 5 days	
	mg/kg	mg/m ²	mg/kg	mg/m ²	mg/kg	mg/m ²	mg/kg	mg/m ²
Highest non-toxic dose (HNTD)	--	--	0.625	13.2	0.187	3.75	0.156	1.94 (or less)
Toxic dose low (TDL)	--	--	1.25	22.5	0.375	7.75	0.313	8.0
Toxic dose high (TDH)	--	--	2.5	47.3	0.75	14.9	1.25	15.9
Lethal dose (LD)	--	--	5.0	105.7	1.5	31.1	2.5	33.6
LD ₅₀	13.38	40.15	--	--	--	--	--	--

Acute Toxicity

At lethal dose or LD₅₀, death occurred in mice, dogs and monkeys within 2 to 8 days. Dogs showed severe, mostly hemorrhagic enterocolitis, severe or marked hypoplasia of the bone marrow, moderate or marked hypocellularity of the lymphoid tissues, marked or moderate renal tubular necrosis, together with azotemia, marked or moderate necrosis of the peripancreatic and omental fat tissue and pancreatitis. Monkeys exhibited severe enterocolitis or colitis, severe atrophy of the lymphoid tissues and moderate to severe hypoplasia of the bone marrow. One of the two monkeys furthermore exhibited severe nephrosis, marked focal myocardial necrosis, myocarditis, severe pancreas atrophy and marked atrophy of prostatic gland and testes.

Subacute Toxicity

Surviving dogs and monkeys showed reversible toxic signs, including dose-related emesis, anorexia, dehydration, weakness, leukocytosis, anemia, hypochloremia, proteinuria and appearance of leukocytes, erythrocytes and casts in the urine. Monkeys showed temporary azotemia and sporadic elevation of the transaminases.

Toxic signs disappeared within two weeks following treatment, and dogs and monkeys did not exhibit histopathology after an observation period from 61 to 129 days, with the exception of one dog that showed marked atrophy of the prostatic gland and one monkey that exhibited possible drug-related interstitial nephritis.

Mutagenicity

Cisplatin has been shown to be mutagenic in *E. coli* after prolonged cultivation of cells with sublethal levels of cisplatin.

Chromosome aberrations were observed in Chinese hamster bone marrow cells after an 8 mg/kg treatment of cisplatin.

In the Ames test, cisplatin was shown to be a mild to moderate mutagen.

Non-clinical findings in mice treated with cisplatin (5 mg/kg intraperitoneally) showed that cisplatin caused direct damage to primordial follicle oocytes, leading to apoptosis.

17 SUPPORTING PRODUCT MONOGRAPHS

1. ^{Pr}CISPLATIN INJECTION BP Sterile solution 1 mg / mL (50 mg and 100 mg cisplatin per vial), submission control 275069, Product Monograph, Pfizer Canada ULC. (OCT 24, 2023)

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

CISPLATIN INJECTION

Cisplatin

Read this carefully before you start taking **CISPLATIN INJECTION** and each time you get an injection. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **CISPLATIN INJECTION**.

Serious Warnings and Precautions

CISPLATIN INJECTION can cause serious and possibly fatal side effects including:

- **Severe allergic reactions** that may happen within minutes of receiving CISPLATIN INJECTION.
- **Serious and fatal Infections**, including sepsis (severe reaction to an infection), which can result from a reduced white blood cell count (cells responsible for fighting against an infection).
- **Serious and fatal bone marrow suppression** which may result in reduced white blood cells and platelets.
- **Neurotoxicity** (damage to the nervous system, including the brain and peripheral nervous system):
 - **Leukoencephalopathy** (change in the matter of the brain). Some cases have been fatal.
 - **Peripheral neuropathy** (damage to the nerves outside of your brain or spinal cord).
 - **Posterior reversible encephalopathy** syndrome (swelling of some parts of the brain).
- **Kidney problems**, including reduced urine output, swelling of legs, ankles or feet.
- **Cardiovascular problems**, such as blood clots in the veins or lungs which can lead to a heart attack or stroke. Some cases have been fatal.

Receiving cisplatin before receiving paclitaxel may increase paclitaxel levels in the blood and increase neutropenia (decreased white blood cells) and neurotoxicity (damage to the nervous system).

What is CISPLATIN INJECTION used for?

CISPLATIN INJECTION is used to treat some types of:

- ovarian cancers
- cancer to the testes
- cancer to the bladder

How does CISPLATIN INJECTION work?

CISPLATIN INJECTION belongs to a group of medicines known as antineoplastic or cytotoxic agents. You may also hear it referred to as a chemotherapy medicine. CISPLATIN INJECTION may be used alone or with other anticancer therapies.

CISPLATIN INJECTION contains platinum and is used as an anticancer drug to interfere with the growth of cancer cells and eventually destroy them.

Cancer cells are like normal cells which have changed so that they grow out of control in the body. Since the growth of normal body cells may also be affected by cisplatin, other effects may also occur (see **What are possible side effects from using CISPLATIN INJECTION**).

What are the ingredients in CISPLATIN INJECTION?

Medicinal ingredients: Cisplatin

Non-medicinal ingredients: Hydrochloric Acid or Sodium Hydroxide is added as a pH adjuster, 9 mg/mL of Sodium Chloride in Water for Injection.

CISPLATIN INJECTION comes in the following dosage forms:

CISPLATIN INJECTION (1 mg/mL) is supplied as a sterile aqueous solution for intravenous use, available in single use glass vials of 10 mL, 50 mL and 100 mL. Each single-use vial is individually packaged in a carton. CISPLATIN INJECTION is preservative-free. The cap colour of the 10 mL, 50 mL and 100 mL vials are yellow, blue and green, respectively.

Do not use CISPLATIN INJECTION if:

- you are allergic to cisplatin or to any of the other ingredients of this medicine (listed in **What are the ingredients in CISPLATIN INJECTION**)
- you have had allergic reactions to similar anti-cancer medicines (like those containing platinum) in the past
- you have kidney problems (unless otherwise told by your healthcare professional)
- you have hearing problems (unless otherwise told by your healthcare professionals)

- you have very low numbers of blood cells (a condition called ‘myelosuppression’). Your healthcare professional will check this with a blood test.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take CISPLATIN INJECTION. Talk about any health conditions or problems you may have, including if you have:

- Have recently received or plan to receive vaccines.
- Are taking medications that can damage the kidney. Your healthcare professional will check on you more regularly.
- Heart problems
- A problem with blood clots forming in your blood vessels, such as:
 - painful inflammation of the veins (thrombophlebitis);
 - blockage of blood vessels in the legs (deep vein thrombosis or DVT);
 - lungs (pulmonary embolism).
- Anaemia or bone marrow depression (such as low red blood cells, low white blood cells or low platelets).
- Any sort of infections (such as sinusitis or tooth abscess).
- Hearing problems.
- Kidney problems.
- Liver disease.
- Numbness or weakness of the arms and legs.
- Dizziness or being light-headed, especially on standing up.
- Problems with your vision.
- Muscle problems.
- Low magnesium or calcium levels.

Other warnings you should know about:

- **Children (under 18 years old):**
 - Hearing problems resulting from use of CISPLATIN INJECTION may be more severe in children, especially those less than 5 years old.
- **Adults (Ages 65 and older):**
 - Adults ages 65 and older may be more likely to experience side effects like reduced bone marrow function, kidney problems, and nerve problems.
- Do not have any vaccinations without talking to your healthcare professional first while you are being treated with CISPLATIN INJECTION.
- **Female patients – Pregnancy and breastfeeding**
 - Avoid becoming pregnant while you are using CISPLATIN INJECTION. It could harm your unborn baby.

- If you are pregnant, able to get pregnant or think you are pregnant, there are specific risks you should discuss with your healthcare professional.
- Use effective birth control each time you have sex during your treatment and for at least 7 months after your last dose.
- If you do get pregnant during your treatment, tell your healthcare professional right away.
- Cisplatin passes into breastmilk. Avoid breastfeeding during your treatment and for 1 month after your last dose.
- **Male patients – Pregnancy**
 - Use effective birth control each time you have sex with a woman who could get pregnant. You should use this birth control during your treatment and for at least 4 months after your last dose.
- **Fertility – female and male patients**
 - Treatment with CISPLATIN INJECTION may affect your ability to have a child in the future. Talk to your healthcare professional if you have questions about this.
- **Tests:** During your treatment with CISPLATIN INJECTION, you will have regular blood and urine tests. The results of these tests will tell your healthcare professional how the treatment is affecting your blood, liver and kidneys. Your healthcare professional will also check you for blood clots, nerve damage and hearing loss.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with CISPLATIN INJECTION:

- Medicines used for the treatment of seizures (e.g., phenytoin, carbamazepine, valproate sodium).
- Medicines that are toxic to the kidneys such as some antibiotics (aminoglycosides) and some anti-cancer drugs, such as ifosfamide.
- Medicines that are removed or eliminated by the kidneys, such as lithium (used for bipolar disorder).
 - CISPLATIN INJECTION may reduce the amount of lithium in the blood when CISPLATIN INJECTION is used together with bleomycin and etoposide (other anti-cancer drugs).
 - Lithium blood levels should be monitored during treatment.
- Medicines that can cause hearing problems (hearing loss or balance problems) such as aminoglycoside antibiotics or loop diuretics.
- Medicines that thin the blood (such as coumarin, warfarin).
- Paclitaxel (used to treat cancer).

How to take CISPLATIN INJECTION

CISPLATIN INJECTION should only be given to you by a healthcare professional who specializes in chemotherapy drugs.

CISPLATIN INJECTION is given by a slow injection into a vein.

Usual dose:

Your healthcare professional will decide what dose of CISPLATIN INJECTION is right for you. They will also decide how often and how long you will receive it. This depends on your condition and other factors, such as:

- your weight,
- your age,
- blood tests,
- how well your kidneys, liver and ears are working,
- whether or not other medicines are being given at the same time.

There will be about 3 to 4 weeks between each dose.

Additional fluid is given before and after your dose of CISPLATIN INJECTION. Since Cisplatin can affect your kidneys, additional fluid can help to keep your kidneys from getting damaged.

Your healthcare professional may change your dose of CISPLATIN INJECTION or stop your treatment completely. This can happen if you experience certain side effects.

Overdose:

This medicine will be given to you in a hospital, under the supervision of a healthcare professional. It is unlikely that you will be given too much or too little, however, tell your healthcare professional if you have any concerns. In case of overdose, you may experience increased side effects. Your healthcare professional may give you other treatments to address the symptoms of these side effects.

If you think you, or a person you are caring for, have taken too much CISPLATIN INJECTION, contact a healthcare professional, hospital emergency department, or regional poison control centre immediately, even if there are no symptoms.

Missed dose:

If you miss a dose, your healthcare professional will decide when you should receive the next one.

What are possible side effects from using CISPLATIN INJECTION?

These are not all the possible side effects you may have when taking CISPLATIN INJECTION. If you experience any side effects not listed here, tell your healthcare professional.

- Fast heart rate (tachycardia)
- Low blood pressure (hypotension)
- Inflammation of the blood vessels of the head (cerebral arteritis)
- Vomiting
- Eating disorder characterized by abnormally low body weight (anorexia)
- Diarrhea
- Inflammation of the mouth (stomatitis)
- Joint pain (arthralgia)
- Muscle pain (myalgia)
- Tuberculosis
- Hair loss (alopecia)
- Abnormal sperm production (abnormal spermatogenesis)
- No sperm count (azoospermia)
- Low magnesium count in blood (hypomagnesemia)
- Low calcium count in blood (hypocalcemia)
- Low sodium count in blood (hyponatremia)
- Low potassium count in blood (hypokalemia)
- Low phosphorus count in blood (hypophosphatemia)
- Fever (pyrexia)
- Lack of energy and strength (asthenia)
- Nose bleeds
- Loss of appetite
- Constipation
- Colour blindness
- Swelling of the optic nerve that connects the eye and brain (papilledema)
- Fatigue
- Dehydration
- High blood pressure (hypertension)
- Enlarged breasts (gynecomastia)

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Get immediate medical help
	Only if severe	In all cases	
Severe allergic reaction (anaphylaxis / anaphylactic reaction): you may experience a sudden itchy rash (hives), swelling of the hands, feet, ankles, face, lips, mouth or throat (which may cause difficulty in swallowing or breathing), flushing and you may feel you are going to faint			X

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Get immediate medical help
	Only if severe	In all cases	
<p>Myelosuppression (decrease in bone marrow function which can affect the production of blood cells)</p> <ul style="list-style-type: none"> • Leukopenia (low white blood cells): signs of infection such as a sore throat and high temperature • Thrombocytopenia (low platelets): abnormal bruising, bleeding • Anemia (low red blood cells): fatigue, loss of energy, pale skin, shortness of breath, weakness 		X	
Infection / Sepsis (severe reaction to an infection): fever and chills, difficulty breathing, sweating, fast heart rate and mental confusion.			X
Pulmonary embolism (blood clot in the lung): chest pain, difficulty breathing, shortness of breath, dizziness, cough, irregular heartbeat.			X
Deep vein thrombosis (blood clot in leg): severe leg pain, swelling in leg, warm skin of red or darkened color around painful area.			X
Heart attack (lack of blood flow to the heart): severe chest pain possible radiating to the jaw or arm, sweating, shortness of breath, nausea			X
Stroke (lack of blood flow to the brain): sudden loss of speech or numbness of part or all of the body, loss of vision or blurred vision, unexplained dizziness and/or sudden falls			X
Kidney failure: reduced urination, joint pain, swelling of feet or lower legs, pain in the lower back or side		X	
Hemolytic anemia (decreased		X	

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Get immediate medical help
	Only if severe	In all cases	
number of red blood cells): fatigue, loss of energy, pale skin, shortness of breath, weakness			
Posterior Reversible Encephalopathy Syndrome (PRES) (swelling of some parts of the brain): headache, confusion, seizures, and visual disturbances (blurred vision, loss of sight), changes in mental function		X	
Leukoencephalopathy (disease of the white matter of the brain): Clumsiness or loss of coordination, difficulty walking, facial drooping, trouble speaking weak muscles, personality changes		X	
Peripheral neuropathy of the sensory nerves: tickling, itching or tingling without cause and sometimes with loss of taste, touch, sight, sudden shooting pains from the neck through the back and into the legs when bending forward		X	
Ototoxicity (damage to the ear): loss of hearing, ringing in the ears, balance problems.		X	
Secondary acute leukemia (type of blood cancer that you can get after chemotherapy or radiation): fever of chills, frequent or severe infections, weight loss, swollen lymph nodes, easy bleeding or bruising.		X	
Nausea and vomiting	X		
Ocular toxicity (vision problems): loss of vision, blurred vision, altered color perception, eye pain.		X	
Extravasation (medication leaking out of the vein into surrounding tissue): painful stinging or burning sensation, swelling, and skin			X

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Get immediate medical help
	Only if severe	In all cases	
discoloration, around the injection site.			
Renal toxicity / nephrotoxicity (problems with your kidneys): swelling in your hands, ankles, feet or other areas of your body, nausea and vomiting, shortness of breath, muscle cramps, loss of appetite, urinating either too much or too little, blood in urine.		X	

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Unopened vials of CISPLATIN INJECTION are stored at room temperature between 15°C and 25°C. Storage of vials should not exceed 25°C. Do not refrigerate or freeze cisplatin solutions since a precipitate will form. Protect from light.

Cisplatin is cytotoxic. This means that it can damage cells. It should be handled by your healthcare professional with protective equipment.

If you want more information about CISPLATIN INJECTION:

- Talk to your healthcare professional
- Find the full Product Monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website:

(<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website <http://www.tevacanada.com>; or by calling 1-800-268-4127 ext. 3; or email druginfo@tevacanada.com .

This leaflet was prepared by Teva Canada Limited, Toronto, Ontario, M1B 2K9.

Last Revised: JUN 25, 2024